Cortistatin-14 (10-250 μg/kg; injected in the footpad or intraperitoneal injection; six times a day) reduces acute neurogenic plasma protein leakage in the hind paw skin of rats caused by mustard oil, as well as carrageenan-induced paw edema in mice, mechanical hyperalgesia, the production of IL-1β and tumor necrosis factor-α, and mild heat injury-induced thermal hyperalgesia[1].
Cortistatin-14 (10 μg; intravenous injection; single dose) plays a regulatory role in the pituitary secretion of male rats[2].
Cortistatin-14 (1-10 nM, intracerebroventricular injection; single dose) has anticonvulsant and neuroprotective effects in rats by binding to somatostatin receptors, which leads to a reduction in the release of excitatory neurotransmitters[3].
| Animal Model: | Hydrochloride-induced rat[3] |
| Dosage: | 1 and 10 nM; single dose |
| Administration: | Intracerebroventricular injection (ICV) |
| Result: | Relieved epilepsy, inhibited neuronal loss, prevented the reduction of immune-active somatostatin and its receptors in the hippocampus, and reduced the release of 3H-D-aspartate under stimulation. |
| Animal Model: | Endotoxin-stimulated mice[1] |
| Dosage: | 10 μg/kg (i.p.); 100 μg/kg (i.p.); 250 μg/kg (i.pl.); six times a day |
| Administration: | Intraperitoneal injection (i.p.); i.pl. |
| Result: | Reduced the concentrations of TNF-α and IL-1β, reduced mustard oil-induced plasma protein extravasation in the dorsal skin, with an inhibition rate of nearly 80%, inhibited plantar thermal hyperalgesia in rats caused by mild thermal injury (51°C, 20 seconds). |
| Animal Model: | Wistar-Kyoto rat[2] |
| Dosage: | 10 μg; single dose |
| Administration: | Intravenous injection (i.v.) |
| Result: | Reduced growth hormone concentrations without affecting LH and FSH concentrations. |
